Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Jazz Venture Partners

Investor type Venture Capital
Founders Adam Gazzaley Andrew Firlik John Harris John Spinale Zack Lynch

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 67
Average round size
info
The average size of a deal this fund participated in
$28M
Portfolio companies 41
Rounds per year 9.57
Lead investments 13
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.39
Exits 5
Key employees 8

Areas of investment

  • Health Care
  • Therapeutics
  • Software
  • Biotechnology
  • Medical
Summary

Jazz Venture Partners appeared to be the VC, which was created in 2015. The venture was found in North America in United States. The main department of described VC is located in the San Francisco.

Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Pear Therapeutics, Akili Interactive Labs, Augment CXM. Among the most successful fund investment fields, there are Consumer Electronics, Artificial Intelligence. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

The current fund was established by Adam Gazzaley, Andrew Firlik, John Harris, John Spinale, Zack Lynch. We also calculated 10 valuable employees in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Jazz Venture Partners, startups are often financed by Intel Capital, Randstad Innovation Fund, Lux Capital. The meaningful sponsors for the fund in investment in the same round are Intel Capital, Arboretum Ventures, Temasek Holdings. In the next rounds fund is usually obtained by Temasek Holdings, Novartis, M Ventures.

The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2016. Speaking about the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The average startup value when the investment from Jazz Venture Partners is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year. This Jazz Venture Partners works on 24 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Jazz Venture Partners:
Typical Co-investors
Jazz Venture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Jazz Venture Partners:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allianz Global Investors Bayern, Germany, Munich
AMD California, Santa Clara, United States
Austin Impact Capital Austin, Texas, United States
Craig Newmark Philanthropies California, San Francisco, United States
Global Infrastructure Partners (GIP) New York, New York, United States
Guangdong Jinxintong Jituan Gufen Co., Ltd. China, Guangdong, Guangzhou
Hanlin Ziben -
Med-Metrix Montvale, New Jersey, United States
MEGVII Beijing, Beijing, China
Meriten Investment Management Germany, Saxony-Anhalt, Zehrental
MNC Group Indonesia, Jakarta Pusat, Jakarta Raya
MP Beteiligungs Germany, Kaiserslautern, Rheinland-Pfalz
PCCW China, Hong Kong, Hong Kong Island
Phoenix Capital Salt Lake City, United States, Utah
Platform Capital Lagos, Lagos, Nigeria
ProVeg International Berlin, Berlin, Germany
Raisin Berlin, Berlin, Germany
Shanghai Yifeng Xinxi China, Shanghai
Shenzhen Success Electronics China, Guangdong, Tianjin

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Form Bio

Biotechnology
Life Science
$30M27 Sep 2022 Austin, Texas, United States

JobGet

Human Resources
Information Technology
Mobile Apps
Recruiting
$40M23 Jun 2022 Boston, Massachusetts, United States

Oma Fertility

Fertility
Health Care
Wellness
$29M21 Jun 2022 Santa Barbara, California, United States

Swing Therapeutics

Biotechnology
Therapeutics
$10M16 Jun 2022 San Francisco, California, United States

KLOwen Braces

Dental
Health Care
$10M20 May 2022 Fort Collins, Colorado, United States

Colossal Biosciences

Biotechnology
$60M09 Mar 2022 Dallas, Texas, United States

HERmd

Health Care
Lifestyle
Wellness
Women's
$10M18 Feb 2022 Cincinnati, Ohio, United States

Yumi

Baby
Food and Beverage
Organic Food
$67M20 Dec 2021 Los Angeles, California, United States

Sounding Board

E-Learning
Human Resources
Information Technology
Software
Training
$30M01 Dec 2021 California, United States
News
Magnus Medical Raises $25M in Series A Financing

– Magnus Medical, Inc. from Burlingame is developing non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments.
– The company raised $25m in Series A funding.
– The round was co-led by Jazz Venture Partners and Red Tree Venture Capital.

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

– Blue Note Therapeutics raised an additional $5.2m in Series A financing, bringing the company’s Series A financing to a total of $31m.
– The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
– The additional proceeds will strengthen Blue Note’s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Jazz Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: